ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The constitutive tyrosine kinase activity of BCR-ABL is responsible for the expansion of myeloid progenitors, and for the last 20 years, tyrosine kinase inhibitors (TKIs) have provided a very efficient treatment for CML [1].